RA PHARMACEUTICALS HAS BEEN BUILDING A BASE FOR 2 YEARS AND IS NOW ON THE VERGE OF BREAKING OUT FROM A CUP AND HANDLE FORMATION. VOLUME HAS INCREASED CONSIDERABLY WHICH IS VERY POSITIVE AS IS ALL THEY INDICATORS. $28 IS THE LEVEL TO WATCH FOR WHAT COULD BE A EPIC BREAKOUT.
AVERAGE ANALYSTS PRICE TARGET $40.33
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of peptide-based drugs for a variety of therapeutic uses. The company's product include RA101495 SC, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria. Ra Pharmaceuticals was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA.
AVERAGE ANALYSTS PRICE TARGET $40.33
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of peptide-based drugs for a variety of therapeutic uses. The company's product include RA101495 SC, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria. Ra Pharmaceuticals was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media